TODD STRATEGY GROUP

Lobbying for GENENTECH, INC. · Biotechnology corporation.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Jul 20, 2026

Lobbying activity 2

Pharmacy

Prescription drug payment reform. Supply chain. Strategic National Stockpile.

Medicare/Medicaid

Medicare and Medicaid payment issues. 340B. Implementation of Inflation Reduction Act of 2022.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.